RxDoctor Payments Data

Christina Woolford, PA

Medical · North Venice, FLNPI 1164906921

Payments from drug & device makers

$3,006in general payments, 2019–2025

Across 72 payments — averaging $41.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$564
  • Cvrx, Inc.$335
  • Abbott$294
  • Biotronik Inc.$239
  • Novo Nordisk$236
  • Boston Scientific$221
  • plus $1K from 17 others

What the payments were for

  • Food & beverage$3,006100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,006 in reported general payments places this provider in the 75th percentile of 2,031 medical providers in Florida.

See all medical providers in Florida

Medicare billing

Part B allowed, 2024
$22,927
Medicare patients
197
Services billed
339

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban94$113,552
EntrestoSacubitril/Valsartan34$46,630
FarxigaDapagliflozin Propanediol27$29,043
XareltoRivaroxaban16$26,237
JardianceEmpagliflozin15$18,053
Metoprolol Succinate192$2,622
Valsartan85$2,459
Ezetimibe71$1,966
Atorvastatin Calcium157$1,889
Rosuvastatin Calcium140$1,799
Losartan Potassium83$724
Spironolactone58$552
Amlodipine Besylate77$532
Enalapril Maleate21$429
ClopidogrelClopidogrel Bisulfate36$322

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$67$113,55294 claims
NovartisEntresto$63$46,63034 claims
AstraZenecaFarxiga$29$29,04327 claims
Johnson & JohnsonXarelto$103$26,23716 claims
Boehringer IngelheimJardiance$25$18,05315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,031 medical providers in Florida.

Other medical in North Venice

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →